Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.41 |
| ▸ | CDK9 | P50750 | 7/20 | 0.41 |
| ▸ | BTK | Q06187 | 13/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004687 | 0.89 | CCNT1 (0.51) | CCNT1CDK9BTK | |
| SCHEMBL16962620 | 0.88 | BTK (0.40) | CCNT1CDK9BTK | |
| SCHEMBL14500401 | 0.88 | CDK9 (0.46) | CCNT1CDK9 | |
| SCHEMBL5008140 | 0.88 | CDK9 (0.40) | CCNT1CDK9BTK | |
| SCHEMBL13994146 | 0.87 | MKNK1 (0.47) | CCNT1CDK9 | |
| SCHEMBL5004818 | 0.84 | CCNT1 (0.49) | CCNT1CDK9BTK | |
| SCHEMBL16963876 | 0.84 | MKNK1 (0.49) | CCNT1CDK9 | |
| SCHEMBL5005396 | 0.83 | CCNT1 (0.41) | CCNT1CDK9BTK | |
| SCHEMBL5008478 | 0.80 | CCNT1 (0.49) | CCNT1CDK9BTK | |
| SCHEMBL16961894 | 0.80 | CCNT1 (0.39) | CCNT1CDK9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | claimed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | claimed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2900671-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900671-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | CCNT1 1580/4885CDK9 428/4885BTK 7/4885 |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | CCNT1 20/4885CDK9 647/4885BTK 3928/4885 |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | CCND2, CCND1, CCNA1 | CCNT1 10/4885CDK9 91/4885BTK 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.